Company AbbVie and Genmab announced the signing of an agreement on cooperation in the development and marketing of three experimental drugs based on antibodies bispecific are working professionals Genmab. Under the agreement, AbbVie will pay Genmab 750 million dollars as an advance, the total amount of payments in the long term can be up to 3.15 billion dollars.
The company will work together to develop methods of differentiated anti-cancer therapies based on antibodies. It is planned joint implementation of programs for the development of antibodies bispecific next generation: Apartman (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4 received by the company Genmab.
In the framework of joint research work on the basis of its own antibodies of both companies, technology companies Genmab DuoBody and ALS technology company AbbVie will be developed of a number of additive differentiated candidate drugs based on antibodies next generation for use in the treatment of cancer from solid tumors to Oncology. The DuoBody technology-CD3 company Genmab is exposed to a targeted cytotoxic T-cells to the tumor, thereby activating the immune response against malignant cells. ALS technology company AbbVie allows the delivery of antitumor agents directly to malignant cells without damaging normal, healthy cells, which provides a more targeted and less toxic method of treatment.
The company will share the commercial load in the promotion of drug Apartman in the United States and Japan, despite the fact that in the future, AbbVie will take responsibility for the withdrawal of the drug on the global market. Company Genmab will retain the profit from sales in the United States and Japan and will receive royalties from global sales of other. As for DuoHexaBody-CD37 and DuoBody-CD3x5T4, as well as any other of candidate drugs developed under this research cooperation, the companies Genmab and AbbVie will share responsibility for international development and the conclusion to the markets of USA and Japan. Company Genmab will retain in parallel with AbbVie to engage in the commercialization of these drugs outside the United States and Japan. In the framework of the research partnership Genmab will hold the first phase of research for these programs. While AbbVie will retain the right to participate in the implementation of these programs.